Abstract
Original language | English |
---|---|
Pages (from-to) | 318-330 |
Number of pages | 13 |
Journal | J Infect Dis |
Volume | 201 |
Issue number | 3 |
DOIs | |
Publication status | Published - Feb 2010 |
Keywords
- abacavir
- anti human immunodeficiency virus agent
- didanosine
- efavirenz
- indinavir
- lamivudine
- lopinavir
- lopinavir plus ritonavir
- nelfinavir
- nevirapine
- saquinavir
- stavudine
- tenofovir
- zalcitabine
- zidovudine
- adult
- aged
- article
- cardiovascular risk
- controlled study
- female
- heart infarction
- human
- Human immunodeficiency virus infection
- major clinical study
- male
- metabolic parameters
- priority journal
- risk assessment
- sensitivity analysis
- chemically induced disorder
- middle aged
- Poisson distribution
- risk factor
- statistical model
- Adult
- Aged
- Anti-HIV Agents
- Female
- HIV Infections
- Humans
- Logistic Models
- Male
- Middle Aged
- Myocardial Infarction
- Poisson Distribution
- Risk Factors
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study: Journal of Infectious Diseases'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study : Journal of Infectious Diseases. / Worm, S.W.; Sabin, C.; Weber, R.; Reiss, P.; El-Sadr, W.; Dabis, F.; De Wit, S.; Law, M.; Monforte, A.D.; Friis-Møller, N.; Kirk, O.; Fontas, E.; Weller, I.; Phillips, A.; Lundgren, J.; Torres, Ferran.
In: J Infect Dis, Vol. 201, No. 3, 02.2010, p. 318-330.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
T2 - Journal of Infectious Diseases
AU - Worm, S.W.
AU - Sabin, C.
AU - Weber, R.
AU - Reiss, P.
AU - El-Sadr, W.
AU - Dabis, F.
AU - De Wit, S.
AU - Law, M.
AU - Monforte, A.D.
AU - Friis-Møller, N.
AU - Kirk, O.
AU - Fontas, E.
AU - Weller, I.
AU - Phillips, A.
AU - Lundgren, J.
AU - Torres, Ferran
N1 - Cited By :501 Export Date: 17 February 2022 CODEN: JIDIA Correspondence Address: Worm, S. W.; University of Copenhagen, Blegdamsvej 3B, Copenhagen 220, Denmark; email: sww@cphiv.dk Chemicals/CAS: abacavir, 136470-78-5, 188062-50-2; didanosine, 69655-05-6; efavirenz, 154598-52-4; indinavir, 150378-17-9, 157810-81-6, 180683-37-8; lamivudine, 134678-17-4, 134680-32-3; lopinavir, 192725-17-0; nelfinavir, 159989-64-7, 159989-65-8; nevirapine, 129618-40-2; saquinavir, 127779-20-8, 149845-06-7; stavudine, 3056-17-5; tenofovir, 147127-19-3, 147127-20-6; zalcitabine, 7481-89-2; zidovudine, 30516-87-1; Anti-HIV Agents Funding details: CT94-1637, CT97-2713 Funding details: QLK2-2000-00773 Funding details: CURE/97-46486 Funding details: 5U01AI042170-10, 5U01AI046362-03, U01-AI069907 Funding details: Abbott Fund Funding details: National Institute of Allergy and Infectious Diseases, NIAID, U01AI042170, U01AI046362, U01AI069907 Funding details: amfAR, The Foundation for AIDS Research Funding details: Bristol-Myers Squibb, BMS Funding details: Pfizer Funding details: GlaxoSmithKline, GSK Funding details: Merck Funding details: Gilead Sciences Funding details: Boehringer Ingelheim Funding details: Food and Drug Administration, FDA Funding details: Cilag Funding details: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SNF Funding details: Agence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS Funding details: Fundación Emilio Soldevilla para la Investigación y el Desarrollo en Economía de la Empresa, FESIDE, FIPSE 3171/00 Funding details: INCLIVA Instituto de Investigación Sanitaria, FIS 99/0887 Funding text 1: Potential conflicts of interest: R.W. has received honoraria or travel grants from Abbott, Boehringer, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, MerckSharpDome, Hoffman–La Roche, and Tibotec. J.L. has received honoraria or travel grants from Abbott, Boehringer, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, MerckSharpDome, Pfizer, Hoffman–La Roche, and Tibotec. All other authors report no potential conflicts. Presented in part: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8–11 February 2009 (abstract 44LB). Financial support is listed after the text. a D:A:D study group members are listed after the text. Funding text 2: Oversight Committee for the Evaluation of Metabolic Complications of Highly Active Antiretroviral Therapy (HAART; collaborative committee with representation from academic institutions, the European Agency for the Valuation of Medicinal Products, the US Food and Drug Administration, the patient community, and all pharmaceutical companies with licensed anti-HIV drugs in the US market: Abbott, Boehringer Ingel-heim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, and Hoffman–La Roche); Health Insurance Fund Council, Amstelveen, the Netherlands (grant CURE/97-46486 to the AIDS Therapy Evaluation Project Netherlands); Agence Nationale de Recherches sur le SIDA (Action Coordonnée no. 7, Cohortes; grant to the Aquitaine Cohort); Australian Government Department of Health and Ageing (funds to Australian HIV Observational Database [AHOD]); National Institute of Allergy and Infectious Diseases, US National Institutes of Health (grant U01-AI069907 to AHOD, grants 5U01AI042170-10 and 5U01AI046362-03 to the Terry Beirn Community Programs for Clinical Research on AIDS); Foundation for AIDS Research (grant to AHOD); Fondo de Investigación Sanitaria (grant FIS 99/0887 to the Barcelona Antiretroviral Surveillance Study [BASS]); Fundación para la Investigación y la Prevención del SIDA en Espanã (grant FIPSE 3171/00 to BASS); BIOMED 1 (grant CT94-1637 to the EuroSIDA study); BIOMED 2 (grant CT97-2713 to the EuroSIDA study); Fifth Framework Program of the European Commission (grant QLK2-2000-00773 to the EuroSIDA study); Bristol-Myers Squibb (grant to the EuroSIDA study and unrestricted educational grant to the Italian Cohort Naive to Antiretrovirals [ICONA] Foundation]); GlaxoSmith-Kline (grant to the EuroSIDA study and unrestricted educational grant to the ICONA Foundation); Boehringer Ingelheim (grant to the EuroSIDA study and unrestricted educational grant to the ICONA Foundation); Hoffman–La Roche (grant to the EuroSIDA study); Abbott (unrestricted educational grant to the ICONA Foundation); Gilead (unrestricted educational grant to the ICONA Foundation); Pfizer (unrestricted educational grant to the ICONA Foundation); Janssen-Cilag (unrestricted educational grant to the ICONA Foundation); Swiss National Science Foundation (grant to the Swiss HIV Cohort Study). References: Mondy, K., Overton, E.T., Grubb, J., Tong, S., Seyfried, W., Powderly, W., Yarasheski, K., Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population (2007) Clinical Infectious Diseases, 44 (5), pp. 726-734. , DOI 10.1086/511679; Glass, T.R., Ungsedhapand, C., Wolbers, M., Weber, R., Vernazza, P.L., Rickenbach, M., Furrer, H., Yerly, S., Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: The Swiss HIV cohort study (2006) HIV Medicine, 7 (6), pp. 404-410. , DOI 10.1111/j.1468-1293.2006.00400.x; Sabin, C.A., D'Arminio, M.A., Friis-Moller, N., Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction (2008) Clin Infect Dis, 46 (7), pp. 1101-1110; Friis-Moller, N., Sabin, C.A., Weber, R., Combination antiretroviral therapy and the risk of myocardial infarction (2003) N Engl J Med, 349 (21), pp. 1993-2003; Friis-Moller, N., Reiss, P., Sabin, C.A., Weber, R., Monforte, A.D., El-Sadr, W., Thiebaut, R., Lundgren, J.D., Class of antiretroviral drugs and the risk of myocardial infarction (2007) New England Journal of Medicine, 356 (17), pp. 1723-1735. , http://content.nejm.org/cgi/reprint/356/17/1723.pdf, DOI 10.1056/NEJMoa062744; Sabin, C.A., Worm, S.W., Weber, R., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration (2008) Lancet, 371 (9622), pp. 1417-1426; Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., Cooper, D.A., A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors (1998) AIDS, 12 (7), pp. F51-F58. , DOI 10.1097/00002030-199807000-00003; Mulligan, K., Grunfeld, C., Tai, V.W., Algren, H., Pang, M., Chernoff, D.N., Lo, J.C., Schambelan, M., Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection (2000) Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 23 (1), pp. 35-43; Fontas, E., Van Leth, F., Sabin, C.A., Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (2004) J Infect Dis, 189 (6), pp. 1056-1074; Lee, G.A., Seneviratne, T., Noor, M.A., Lo, J.C., Schwarz, J.-M., Aweeka, F.T., Mulligan, K., Grunfeld, C., The metabolic effects of lopinavir/ritonavir in HIV-negative men (2004) AIDS, 18 (4), pp. 641-649. , DOI 10.1097/00002030-200403050-00008; Sax, P.E., Kumar, P., Tolerability and safety of HIV protease inhibitors in adults (2004) Journal of Acquired Immune Deficiency Syndromes, 37 (SUPPL. 1), pp. 1111-1124. , DOI 10.1097/01.qai.0000138420.38995.86; Ledergerber, B., Furrer, H., Rickenbach, M., Lehmann, R., Elzi, L., Hirschel, B., Cavassini, M., Yerly, S., Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study (2007) Clinical Infectious Diseases, 45 (1), pp. 111-119. , DOI 10.1086/518619; Riddler, S.A., Haubrich, R., Dirienzo, A.G., Peeples, L., Powderly, W.G., Klingman, K.L., Garren, K.W., Mellors, J.W., Class-sparing regimens for initial treatment of HIV-1 infection (2008) New England Journal of Medicine, 358 (20), pp. 2095-2106. , http://content.nejm.org/cgi/reprint/358/20/2095.pdf, DOI 10.1056/NEJMoa074609; Echeverria, P., Alonso, M., Portilla, J., (2007) Similar Antiviral Efficacy and Tolerability between Efavirenz and Lopinavir/ritonavir Administered with Abacavir/lamivudine (KIVEXA) in Antiretroviral-naive Patients: A Multicentre, Randomized Study (LAKE Study), , Program and abstracts of the 4th International AIDS Society Conference. Geneva, Switzerland: International AIDS Society, Abstract WEPEB022; Anderson, K.M., Wilson, P.W., Odell, P.M., Kannel, W.B., An updated coronary risk profile: A statement for health professionals (1991) Circulation, 83 (1), pp. 356-362; Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., Pajak, A., Myocardial infarction and coronary deaths in the World Health Organization MONICA project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents (1994) Circulation, 90 (1), pp. 583-612; Friis-Moller, N., Weber, R., Reiss, P., Cardiovascular disease risk factors in HIV patients (2003) AIDS, 17 (8), pp. 1179-1193; Shafran, S.D., Mashinter, L.D., Roberts, S.E., The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations (2005) HIV Med, 6 (6), pp. 421-425; Leon, A., Martinez, E., Sarasa, M., Lopez, Y., Mallolas, J., De Lazzari, E., Laguno, M., Gatell, J.M., Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues (2007) Journal of Antimicrobial Chemotherapy, 60 (4), pp. 824-830. , DOI 10.1093/jac/dkm285; Arnaiz, J.A., Mallolas, J., Podzamczer, D., Gerstoft, J., Lundgren, J.D., Cahn, P., Fatkenheuer, G., Gatell, J.M., Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load (2003) AIDS, 17 (6), pp. 831-840. , DOI 10.1097/00002030-200304110-00008; Dragsted, U.B., Gerstoft, J., Pedersen, C., Peters, B., Duran, A., Obel, N., Castagna, A., Lundgren, J.D., Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 trial (2003) Journal of Infectious Diseases, 188 (5), pp. 635-642. , DOI 10.1086/377288; Dragsted, U.B., Gerstoft, J., Youle, M., Fox, Z., Losso, M., Benetucci, J., Jayaweera, D.T., Lundgren, J.D., A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: The MaxCmin2 trial (2005) Antiviral Therapy, 10 (6), pp. 735-743; Walmsley, S., Ruxrungtham, K., Slim, J., Ward, D., Larson, P., Raffi, F., (2007) Saquinavir/r BID Versus Lopinavir/r BID Plus Emtricitabine/tenofovir QD As Initial Therapy in HIV-1 Infected Patients: the Gemini Study., , Program and abstracts of the 11th European AIDS Conference. Paris, France: European AIDS Clinical Society, Abstract PS1-4; Madden, E., Lee, G., Kotler, D.P., Association of antiretroviral therapy with fibrinogen levels in HIV-infection (2008) AIDS, 22 (6), pp. 707-715; Dube, M.P., Shen, C., Greenwald, M., Mather, K.J., No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: A placebo-controlled trial (2008) Clin Infect Dis, 47 (4), pp. 567-574; Jackson, A., Patel, N., Lo, G., Gazzard, B., Moyle, G., (2007) Effects of Atazanavir or Saquinavir Once Daily with Ritonavir 100 Mg and Tenofovir/emtricitabine As Initial Therapy for HIV-1 Infection on Peripheral Glucose Disposal: A Randomized Open-label Study, , Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, Abstract 818; Vrouenraets, S.M.E., Fernandez Garcia, E., Jackson, A., Saquinavir versus atazanavir once daily, each boosted with 100 mg ritonavir and combined with tenofovir/emtricitabine, result in comparable lipid changes after 24 weeks in treatment-naive HIV-infected patients (2008) Antivir Ther, 13 (SUPPL. 4), pp. A46; Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients (2008) AIDS, 22 (14), pp. F17-F24; Lang, S., Mary-Kause, M., Cotte, L., (2009) Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction: A Case-control Study Nested Within CO4, , Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, Abstract 43; Cooper, D., Bloch, M., Humphries, A., (2009) Simplification with Fixed-dose Tenofovir/emtricitabine or Abacavir/lamivudine in Adults with Supressed HIV Replication: the STEAL Study, A Randomised, Open-label 96-week, Non-inferiority Trial, , Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, Abstract 576; Benson, C., Ribaudo, H., Zheng, E., (2009) No Association of Abacavir Use with Risk of Myocardial Infarction or Severe Cardiovascular Disease Events: Results from ACTG A5001, , Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, Abstract 721; Cutrell, A., Brothers, C., Yeo, J., Hernandez, J., Lapierre, D., Abacavir and the potential risk of myocardial infarction (2008) Lancet, 371 (9622), p. 1413; Gallant, J.E., Staszewski, S., Pozniak, A.L., Dejesus, E., Suleiman, J.M.A.H., Miller, M.D., Coakley, D.F., Cheng, A.K., Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial (2004) Journal of the American Medical Association, 292 (2), pp. 191-201. , DOI 10.1001/jama.292.2.191; Izzedine, H., Isnard-Bagnis, C., Hulot, J.-S., Vittecoq, D., Cheng, A., Jais, C.K., Launay-Vacher, V., Deray, G., Renal safety of tenofovir in HIV treatment-experienced patients (2004) AIDS, 18 (7), pp. 1074-1076. , DOI 10.1097/00002030-200404300-00019; Mocroft, A., Kirk, O., Gatell, J., Reiss, P., Gargalianos, P., Zilmer, K., Beniowski, M., Lundgren, J.D., Chronic renal failure among HIV-1-infected patients (2007) AIDS, 21 (9), pp. 1119-1127. , DOI 10.1097/QAD.0b013e3280f774ee, PII 0000203020070531000005; Martinez, E., Gnarini, M., De Lazzari, E., (2007) Long-term Trends in Plasma Lipids and Glucose in Antiretroviral Naive HIV-infected Patients Starting Highly Active Antiretroviral Therapy, , Program and abstracts of the 4th International AIDS Society Conference. Geneva, Switzerland: International AIDS Society, Abstract WESS102; Arribas, J.R., Pozniak, A.L., Gallant, J.E., Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis (2008) J Acquir Immune Defic Syndr, 47 (1), pp. 74-78; Sabin, C., Worm, S.W., Phillips, A., Lundgren, J.D., Abacavir and increased risk of myocardial infarction-authors' reply [letter] (2008) Lancet, 372 (9641), pp. 804-805; Van, L.F., Phanuphak, P., Stroes, E., Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 (2004) PLoS Med, 1 (1), pp. e19; Sankatsing, R., Franssen, R., Hassink, E., Nevirapine increases highdensity lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production (2009) Arterioscler Thromb Vasc Biol, 29 (9), pp. 1336-1341; Phillips, A.N., Carr, A., Neuhaus, J., Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: Exploratory analyses from the SMART trial (2008) Antivir Ther, 13 (2), pp. 177-187; Bender, R., Lange, S., Adjusting for multiple testing-when and how? (2001) J Clin Epidemiol, 54 (4), pp. 343-349; Thompson, J.R., Re: "Multiple comparisons and related issues in the interpretation of epidemiologic data" [invited commentary] (1998) Am J Epidemiol, 147 (9), pp. 801-806; Hammer, S.M., Eron Jr., J.J., Reiss, P., Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel (2008) JAMA, 300 (5), pp. 555-570
PY - 2010/2
Y1 - 2010/2
N2 - Background. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Methods. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of antiretroviral drugs, with >30,000 person-years of exposure. Results. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic parameters. Conclusions. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provide. © 2009 by the Infectious Diseases Society of America. All rights reserved.
AB - Background. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Methods. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of antiretroviral drugs, with >30,000 person-years of exposure. Results. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic parameters. Conclusions. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provide. © 2009 by the Infectious Diseases Society of America. All rights reserved.
KW - abacavir
KW - anti human immunodeficiency virus agent
KW - didanosine
KW - efavirenz
KW - indinavir
KW - lamivudine
KW - lopinavir
KW - lopinavir plus ritonavir
KW - nelfinavir
KW - nevirapine
KW - saquinavir
KW - stavudine
KW - tenofovir
KW - zalcitabine
KW - zidovudine
KW - adult
KW - aged
KW - article
KW - cardiovascular risk
KW - controlled study
KW - female
KW - heart infarction
KW - human
KW - Human immunodeficiency virus infection
KW - major clinical study
KW - male
KW - metabolic parameters
KW - priority journal
KW - risk assessment
KW - sensitivity analysis
KW - chemically induced disorder
KW - middle aged
KW - Poisson distribution
KW - risk factor
KW - statistical model
KW - Adult
KW - Aged
KW - Anti-HIV Agents
KW - Female
KW - HIV Infections
KW - Humans
KW - Logistic Models
KW - Male
KW - Middle Aged
KW - Myocardial Infarction
KW - Poisson Distribution
KW - Risk Factors
UR - http://www.ncbi.nlm.nih.gov/pubmed/20039804
U2 - 10.1086/649897
DO - 10.1086/649897
M3 - Article
C2 - 20039804
VL - 201
SP - 318
EP - 330
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 3
ER -